Sign in
Taking people in United StatesNo phase

Comparing catheter valve replacement with open surgery for bicuspid aortic valve narrowing

Compares two ways to replace the valve in severe bicuspid aortic stenosis.

Key facts

Who runs it
Cedars-Sinai Medical Center
Where
Los Angeles, United StatesSee the site
Trial code
Registry title
TAVR vs SAVR in Severe Bicuspid Aortic Stenosis
Status
Recruiting
People taking part
1,200 people, planned
Started
23 Jul 2026
Expected to end
10 May 2040
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Transcatheter Aortic Valve Replacement
  • the open chest surgery to replace the aortic valve
Record updated
14 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 50 or older with severe narrowing of the aortic valve (aortic stenosis) and a bicuspid valve (two flaps instead of three). People are randomly given either a catheter valve (TAVR) or open-chest surgery (SAVR).

Age
50 years or older
Sex
All sexes
Disease stage
Severe aortic stenosis. A local heart team must judge that a tissue valve can be used. The person cannot have, or chose not to have, a mechanical valve or Ross procedure. A bicuspid valve must be confirmed on a CT scan.
Earlier treatment
People cannot join if they already have a TAVR or SAVR valve. They also cannot join after a heart or blood vessel procedure within 30 days before randomization.
Biomarker or test result
A gated contrast CT scan is needed. It must be good enough for central lab review.

Main reasons for not taking part

  • Pregnancy or breastfeeding
  • Very high risk for TAVR or SAVR, or much higher risk with one than the other
  • Widened aorta (45mm or more), or other heart surgery planned with the valve surgery
  • Stroke or TIA within 90 days, or LVEF below 25% within 90 days
  • Severe kidney (eGFR < 30 ml/min), lung (FEV1 < 50% predicted) or liver disease

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • 50 years of age or older at time of consent
  • Severe AS deemed suitable for a bioprosthesis by a local heart team (unsuitable or patient declined a mechanical valve or Ross procedure, following demonstration of evidence-based shared decision making with a validated decision-aid(1)
  • Gated contrast CT available and suitable for core laboratory analysis
  • BAV anatomy confirmed by CT core laboratory analysis

Who cannot take part

  • Recent cardiovascular intervention within 30 days prior to randomization
  • Site plan for treatment of concomitant non-coronary cardiovascular disease in the event of randomization to surgery (for instance, concomitant valve surgery, septal defect or coarctation repair, aorta or root replacement or repair)
  • Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation, or mechanical heart assistance within 30 days prior to randomization
  • Stroke or transient ischemic attack (TIA) within 90 days prior to randomization
  • Severe lung disease (FEV1 < 50% predicted), unresolved prior to randomization
  • In the presence of coronary artery disease deemed necessary for revascularization in the event of randomization to SAVR or TAVR, Syntax score ≥ 32 or deemed unsuitable for PCI, or deemed unsuitable for coronary artery bypass grafting (CABG)
  • History of liver disease defined as MELD Score ≥ 10 or Child-Pugh Class B or C
  • Unable to complete the KCCQ due cognitive impairment or other medical condition
  • Associated aortopathy (AA≥45mm by maximal cross-sectional dimension, as confirmed by CT core laboratory analysis, or AA<45mm but site plan for surgery of the aorta in the event of randomization to surgery
  • Leukopenia (WBC < 3000 cells/µL), anemia (Hgb < 8 g/dL), Thrombocytopenia (Plt < 50,000 cells/µL) on latest available labs within 30 days prior to randomization
  • LVEF < 25% within 90 days prior to randomization
  • Renal insufficiency (eGFR < 30 ml/min per the Cockcroft-Gault formula)
  • Presence of an existing TAVR or SAVR device
  • Pregnancy or lactation
  • Extreme or prohibitive TAVR or SAVR risk, adjudicated by Patient Selection Committee (PSC) Review
  • Active enrollment in another investigational study
  • Disproportionate TAVR vs SAVR risk, as adjudicated by the patient selection committee
  • Plan to use any device other than commercially approved Edwards balloon expandable or Medtronic self-expanding TAVR

Where in United States

  • Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Mitch Gheorghiu, MDTaking people

About the trial

What the trial wants to find out

The study is a multicenter, randomized superiority trial of standard of care therapies for severe aortic stenosis (AS) in patients with a bicuspid aortic valve (BAV).

Read full original descriptionShow less

The two primary comparators in this study are: Transcatheter Aortic Valve Replacement (TAVR), and Surgical Aortic Valve Replacement (SAVR).

TAVR is a minimally invasive transcatheter procedure to treat aortic valve disease..

SAVR is involving the open chest surgery to replace the aortic valve.

The devices and international procedures in this Trial (TAVR or SAVR) are commercially approved by the FDA.

Consented patients who are qualifying for the Trial will be randomized 1:1, meaning they will have an equal chance to be treated with either TAVR or SAVR procedure.

Consented patients who will not qualify for the randomized part of the study will be followed up clinically in either TAVR or SAVR Registry arms.

The study objective is to provide evidence to guide patients and their providers on the most appropriate therapy for valve replacement on this particular BAV anatomy.

The 2 groups in the trial

  • Transcatheter Aortic Valve Replacement TAVROther group

    percutaneous approach as modality of treatment

    Treatment: Transcatheter Aortic Valve Replacement

  • Surgical Aortic Valve Replacement SAVRExisting treatment, for comparison

    open chest approach as modality of treatment

    Treatment: the open chest surgery to replace the aortic valve

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Bicuspid Aortic Valve Replacement: EvaLuatIon of transcathetEr VERsus Surgery (BELIEVERS) Trial
Plain-language title
Comparing catheter valve replacement with open surgery for bicuspid aortic valve narrowingGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
14 August 2026